Trial Profile
Efficacy and Tolerability of Mirabegron Compared to Oxybutynin Chloride Immediate Release for Neurogenic Detrusor Overactivity in Persons With Chronic Spinal Cord Injury: A Randomized, Double-Blind, Controlled, Cross-Over Clinical Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary) ; Oxybutynin (Primary)
- Indications Detrusor instability; Overactive bladder
- Focus Therapeutic Use
- Acronyms MOSET-SCI
- 14 Dec 2019 Status changed from not yet recruiting to recruiting.
- 08 Aug 2018 Planned initiation date changed from 8 Jan 2018 to 1 Sep 2018.
- 29 Nov 2017 Planned initiation date changed from 15 Sep 2017 to 8 Jan 2018.